Healthcare ❯ Vaccines

COVID-19 Vaccines

mRNA Technology FDA Regulations Insurance Coverage Vaccine Efficacy Moderna and Pfizer FDA Approval Approval Process Comirnaty Covaxin Oxford-AstraZeneca Vaccine Access Restrictions RSV Vaccines Vaccine Controversies Vaccine Policy mRNA Vaccines Moderna's COVID-19 Vaccine Comparative Analysis Spikevax Affordable Care Act Updated Vaccines

CDC Tracks BA.3.2, a New COVID Variant With Strong Lab Immune Escape and Low U.S. Prevalence

Officials cite lab signs of immune escape, urging more real‑world data.

Stories older than 24h

Moderna Reaches Up to $2.25 Billion LNP Patent Settlement, Pays $950 Million Upfront

Pfizer Sets 2026 Targets Below Wall Street as COVID Sales Fade, Patent Pressure Builds

Greene Urges DOJ to Drop Charges Against Surgeon on Trial for COVID-19 Vaccine Fraud